Nevro (NVRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are ...

Nevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago. These figures are ...

Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...

NEVRO ($NVRO) is expected to release its quarterly earnings data on Tuesday, March 4th after market close, per Finnhub. Analysts are expecting revenue of $104,594,880 ...

Reports Q4 revenue $105.5M, consensus $102.61M. Cash, cash equivalents and short-term investments totaled $292.5M as of December 31, 2024, an ...

The Redwood City, California-based company said it had a loss of $1.41 per share. Losses, adjusted for one-time gains and costs, came to 64 cents per share. The results surpassed Wall Street ...

What Are the BATMMAAN Stocks? If you're ready to move beyond Magnificent Seven stocks, there's a new acronym on Wall Street with one key addition.